Anixa Biosciences Inc 8-K, filed Oct 4, 2021
Anixa Biosciences Inc (ANIX)
About this 8-K
Anixa Biosciences Inc filed this 8-K on October 4, 2021, reporting on events of October 1, 2021.
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission
File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
| (Former name or former address, if changed since last report) |
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events |
On October 1, 2021, patient recruitment commenced for the initial clinical trial of the preventative breast cancer vaccine being developed by Cleveland Clinic, the U.S. Department of Defense and Anixa Biosciences, Inc. The study titled, “Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic Triple-Negative Breast Cancer at High Risk of Recurrence” is being performed at Cleveland Clinic and is an open-label, dose-escalation trial in which participants will be treated with successively higher doses of the vaccine. It is estimated that 18-24 participants will be treated in this trial and the trial is estimated to take approximately one year to complete. More details regarding the trial can be found at https://www.clinicaltrials.gov/ct2/show/NCT04674306?recrs=b&cond=Breast+Cancer&cntry=US&state=US%3AOH&draw=2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 4, 2021
| ANIXA BIOSCIENCES, INC. | ||
| By: | /s/ Amit Kumar | |
| Name: | Dr. Amit Kumar | |
| Title: | President and Chief Executive Officer | |